Prestige Consumer Healthcare (PBH) EBITDA (2010 - 2025)

Prestige Consumer Healthcare's EBITDA history runs 16 years deep, the most recent figure standing at $82.5 million for Q4 2025.

• On a quarterly basis, EBITDA fell 10.3% year-over-year to $82.5 million in Q4 2025; TTM through Dec 2025 was $322.3 million, a 2.47% decrease from a year earlier, with the FY2025 full-year figure at $336.8 million, down 1.65% from the prior year.
• EBITDA improved to $82.5 million in Q4 2025 per PBH's latest filing, from $79.7 million in the prior quarter.
• Across five years, EBITDA topped out at $92.0 million in Q4 2024 and bottomed at -$281.0 million in Q1 2023.
• The 5-year median for EBITDA is $83.5 million (2021), against an average of $64.6 million.
• Across the five-year window, EBITDA sank 462.93% in 2023 and surged 129.24% in 2024, its largest moves.
• Year by year, EBITDA stood at $82.6 million in 2021, then increased by 5.56% to $87.2 million in 2022, then declined by 0.4% to $86.8 million in 2023, then increased by 5.91% to $92.0 million in 2024, then declined by 10.3% to $82.5 million in 2025.
• Per Business Quant, the three latest PBH EBITDA figures stand at $82.5 million (Q4 2025), $79.7 million (Q3 2025), and $71.8 million (Q2 2025).